Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 24;11(11):2877.
doi: 10.3390/biomedicines11112877.

The Antioxidative Effects of Flavones in Hypertensive Disease

Alexandria Porcia Haynes  1 , Selam Desta  1   2 , Taseer Ahmad  1   3 , Kit Neikirk  4 , Antentor Hinton  4 , Nathaniel Bloodworth  1 , Annet Kirabo  1
Affiliations
Review

The Antioxidative Effects of Flavones in Hypertensive Disease

Alexandria Porcia Haynes et al. Biomedicines. .

Abstract

Hypertension is the leading remediable risk factor for cardiovascular morbidity and mortality in the United States. Excess dietary salt consumption, which is a catalyst of hypertension, initiates an inflammatory cascade via activation of antigen-presenting cells (APCs). This pro-inflammatory response is driven primarily by sodium ions (Na+) transporting into APCs by the epithelial sodium channel (ENaC) and subsequent NADPH oxidase activation, leading to high levels of oxidative stress. Oxidative stress, a well-known catalyst for hypertension-related illness development, disturbs redox homeostasis, which ultimately promotes lipid peroxidation, isolevuglandin production and an inflammatory response. Natural medicinal compounds derived from organic materials that are characterized by their anti-inflammatory, anti-oxidative, and anti-mutagenic properties have recently gained traction amongst the pharmacology community due to their therapeutic effects. Flavonoids, a natural phenolic compound, have these therapeutic benefits and can potentially serve as anti-hypertensives. Flavones are a type of flavonoid that have increased anti-inflammatory effects that may allow them to act as therapeutic agents for hypertension, including diosmetin, which is able to induce significant arterial vasodilation in several different animal models. This review will focus on the activity of flavones to illuminate potential preventative and potential therapeutic mechanisms against hypertension.

Keywords: NADPH oxidase; diosmetin; flavone; flavonoid; hypertension; inflammation; molecular pharmacology; protein kinase C (PKC).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
Salt-sensitive hypertension pathway.
Figure 2
Figure 2
Flavonoid carbon numbers and ring names. (A) benzene ring; (B) phenyl ring; (C) heterocyclic ring.
Figure 3
Figure 3
Types of flavonoids.
Figure 4
Figure 4
Structure of diosmetin.
Figure 5
Figure 5
Illustration of Smad3 phosphorylation inhibition by flavones through the inhibition of LSD1A and the JAK2/STAT3 pathway.
Figure 6
Figure 6
Illustration of flavones inhibiting increased intracellular calcium ion concentration through inhibition of PKC-mediated phosphorylation of p47phox.
Figure 7
Figure 7
Flavonoids play a role in scavenging ROS through the activation of the Nrf2/HO-1 pathway and potentially direct intracellular ROS scavenging.
Figure 8
Figure 8
Flavones inhibit hypertension associated inflammation by inhibiting AhR and CYP1A1.
Figure 9
Figure 9
MRP-1 stops the intracellular anti-inflammatory response through inhibition of GSH-mediated ROS and lipid peroxide scavenging; inhibition of MRP-1 by diosmetin supports this intracellular anti-inflammatory response.
Figure 10
Figure 10
Flavone activity in different hypertensive pathways and potential hypertension-inhibiting mechanisms.
See this image and copyright information in PMC

References

    1. GBD 2013 Risk Factors Collaborators. Forouzanfar M.H., Alexander L., Anderson H.R., Bachman V.F., Biryukov S., Brauer M., Burnett R., Casey D., Coates M., et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:2287–2323. doi: 10.1016/S0140-6736(15)00128-2. - DOI - PMC - PubMed
    1. Whelton P.K., Carey R.M., Aronow W.S., Casey D.E., Jr., Collins K.J., Himmelfarb C.D., DePalma S.M., Gidding S., Jamerson K.A., Jones D.W., et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13–e115. doi: 10.1161/hyp.0000000000000065. - DOI - PubMed
    1. Unger T., Borghi C., Charchar F., Khan N.A., Poulter N.R., Prabhakaran D., Ramirez A., Schlaich M., Stergiou G.S., Tomaszewski M., et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75:1334–1357. doi: 10.1161/HYPERTENSIONAHA.120.15026. - DOI - PubMed
    1. Elijovich F., Laffer C.L., Sahinoz M., Pitzer A., Ferguson J.F., Kirabo A. The Gut Microbiome, Inflammation, and Salt-Sensitive Hypertension. Curr. Hypertens. Rep. 2020;22:79. doi: 10.1007/s11906-020-01091-9. - DOI - PMC - PubMed
    1. Patrick D.M., Van Beusecum J.P., Kirabo A. The role of inflammation in hypertension: Novel concepts. Curr. Opin. Physiol. 2021;19:92–98. doi: 10.1016/j.cophys.2020.09.016. - DOI - PMC - PubMed

LinkOut - more resources